Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte (Nasdaq:VCYT) will participate in two upcoming investor conferences. Management presents at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, and at the Jefferies Global Healthcare Conference in New York on June 4, 2026.
Both events feature live and replay webcasts via Veracyte’s investor relations site.
Veracyte (Nasdaq:VCYT) received Medicare MolDX coverage for its TrueMRD Monitoring Test in muscle-invasive bladder cancer (MIBC). The test is covered for recurrence monitoring after curative-intent treatment and becomes orderable on June 1, 2026, marking Veracyte’s first commercial molecular residual disease offering.
According to Veracyte, the whole-genome, tumor-informed TrueMRD platform showed a median detection of recurrence 131 days earlier than imaging in the PAGER study of 112 MIBC patients. The platform is also used in ongoing TOMBOLA and NEO-BLAST trials, supporting its role in evolving MIBC treatment and surveillance strategies.
Veracyte (Nasdaq: VCYT) reported Q1 2026 results: total revenue $139.1M (+21% YoY) and testing revenue $135.1M (+26% YoY). Decipher revenue grew 30% to $86.5M; Afirma grew 21% to $46.4M. GAAP net income was $28.7M and adjusted EBITDA was $42.8M (30.8% of revenue). Cash from operations was $35.2M; cash and short-term investments totaled $439.1M as of March 31, 2026. Company raised 2026 revenue guidance to $582M–$592M and testing revenue to $570M–$580M, and raised adjusted EBITDA margin guidance to >26%.
Veracyte (Nasdaq: VCYT) announced that more than 15 studies on the Decipher portfolio will be presented at the AUA 2026 meeting (May 15–18, Washington, D.C.).
Highlights include Decipher Bladder molecular subtyping data linking subtypes to outcomes and responses to neoadjuvant chemo‑immunotherapy, and national‑scale Decipher Prostate real‑world analyses powered by the Decipher GRID database with more than a decade of data. Veracyte will be at booth #3405.
Veracyte (Nasdaq: VCYT) will release first quarter 2026 financial results after market close on May 5, 2026.
Management will host a conference call and live webcast at 4:30 p.m. Eastern Time on May 5, 2026 to discuss results and provide a business update; a replay will be available on the company’s investor website.
Veracyte (Nasdaq: VCYT) named Kevin Haas, Ph.D., as Chief Development and Technology Officer, effective March 24, 2026. The newly created role will oversee end-to-end product development across assays, software, bioinformatics, and the product development program office to support MRD and multi-omics initiatives.
Dr. Haas brings more than 15 years of life sciences experience, including senior technology and bioinformatics leadership roles at Myriad and Counsyl, and holds a Ph.D. in chemical engineering from UC Berkeley.
Veracyte (Nasdaq: VCYT) reported strong fourth-quarter and full-year 2025 results: Q4 total revenue $140.6M (+19%), testing revenue $135.8M (+21%), and full-year revenue $517.1M (+16%).
GAAP net income was $41.1M for Q4 and $66.4M for 2025; cash from operations was $52.6M in Q4 and $136.3M for the year. The company reiterates 2026 revenue guidance of 10–13% ($570M–$582M) and expects adjusted EBITDA margin of ~25%.
Veracyte (Nasdaq: VCYT) will present more than 15 abstracts at the 2026 ASCO Genitourinary Cancers Symposium, Feb 26–28 in San Francisco, highlighting Decipher Prostate and Bladder tests and the upcoming TrueMRD™ MIBC test.
Presentations include SURE‑02 phase II results, HCRN GU 20-444 oral data, and multiple real-world Decipher and GRID analyses supporting clinical decision-making in urologic cancers.
Veracyte (Nasdaq: VCYT) will present at two investor conferences in March 2026: a presentation at the Raymond James Institutional Investors Conference in Orlando on March 3, 2026 at 8:05 AM ET, and a fireside chat at the Leerink Partners Global Health Conference in Miami on March 9, 2026 at 10:40 AM ET.
Live audio webcasts will be available via the company investor website, with replays accessible for 90 days after each live broadcast.
Veracyte (Nasdaq: VCYT) will release fourth-quarter and full-year 2025 financial results after market close on Wednesday, February 25, 2026. Management will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a general business update.
The live webcast and replay will be available on the company website, and dial-in details require registration via the company-provided links.